Balchem Corporation

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $175M normalized FCF base (slightly above TTM $171.4M); 7% annual growth years 1-5, 4.5% years 6-10; 8% discount rate; 3% terminal growth; -$103.54M net debt; 31.88M shares outstanding.

Reasoning: Balchem is a stable, high-margin specialty chemicals/nutrition business with consistent FCF conversion, which supports a standard unlevered DCF. Growth assumptions reflect its historical high-single-digit organic growth plus bolt-on M&A, moderating over time; the discount rate reflects its low-beta, diversified end markets.